Table 1 Clinical characteristics of TNBC patients included in the study
Variable | Whole cohort N = 54 | Discovery cohort N = 24 | Validation cohort N = 30 |
|---|---|---|---|
Age; median (range) | 47.88 (27.19–78.92) | 46.88 (30.33–78.07) | 48.49 (27.19–78.92) |
cT | |||
 cTx | 5 (9.3%) | 2 (8.3%) | 3 (10.0%) |
 cT1–2 | 40 (74.1%) | 16 (66.6%) | 24 (80.0%) |
 cT3–4 | 9 (16.6%) | 6 (25.1%) | 3 (10.0%) |
cN | |||
 cNx | 4 (7.4%) | 2 (8.3%) | 2 (6.7%) |
 cN0 | 32 (59.3%) | 14 (58.4%) | 18 (60.0%) |
 cN+ | 18 (33.3%) | 8 (33.3%) | 10 (33.3%) |
Ki67 in biopsy | |||
 Missing value | 10 (18.5%) | 7 (29.2%) | 3 (10.0%) |
 ki67 < =50% | 17 (31.6%) | 7 (29.2%) | 10 (33.3%) |
 ki67 > 50% | 26 (49.9%) | 10 (41.6%) | 17 (56.7%) |
Type of NAC | |||
 Taxanes | 14 (25.9%) | 5 (20.8%) | 9 (30.0%) |
 Anthracyclines | 1 (1.9%) | 0 (0%) | 1 (3.3%) |
 Taxanes and anthracyclines | 39 (72.2%) | 19 (79.2%) | 20 (66.7%) |
RCB | |||
 RCB = 0 | 19 (35.2%) | 10 (41.7%) | 9 (30.0%) |
 RCB > 0 | 35 (64.8%) | 14 (58.3%) | 21 (70.0%) |
RCB: | |||
 RCB = 0 | 19 (35.2%) | 10 (41.7%) | 9 (30.0%) |
 RCB = 1 | 8 (14.8%) | 3 (12.5%) | 5 (16.7%) |
 RCB = 2 | 19 (35.3%) | 6 (25.0%) | 13 (43.3%) |
 RCB = 3 | 8 (14.8%) | 5 (20.8%) | 3 (10.0%) |